Browse · Source documents
Source documents 18,539–18,837
18,539–18,837 of 57,973
- Form 4: Emergent BioSolutions Inc. (EBS), Zoon Kathryn C, transaction 05/26/2022
- Form 4: Emergent BioSolutions Inc. (EBS), Zoon Kathryn C, transaction 06/09/2022
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Benito Simon X, transaction 01/04/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Benito Simon X, transaction 02/16/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Benito Simon X, transaction 03/16/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Benito Simon X, transaction 04/16/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Benito Simon X, transaction 05/13/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Dansey Roger D, transaction 05/13/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 02/26/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 03/05/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 03/11/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 08/10/2020
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 11/10/2020
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 01/15/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 02/26/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 03/05/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 03/11/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 04/21/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kies Peter, transaction 12/15/2020
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 02/01/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 02/26/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 03/05/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 03/11/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Kim Jong Joseph, transaction 12/29/2020
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Miller Ann Calby, transaction 03/21/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 01/27/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 02/01/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 02/26/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 03/11/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 03/25/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Shepard Jay, transaction 01/15/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Shepard Jay, transaction 05/13/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 02/26/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 03/05/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 03/11/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 04/21/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 05/13/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Weiner David B., transaction 12/15/2020
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Yarno Wendy L, transaction 05/13/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Yarno Wendy L, transaction 12/05/2020
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Zoth Lota S., transaction 01/03/2021
- Form 4: Inovio Pharmaceuticals, Inc. (INO), Zoth Lota S., transaction 05/13/2021
- Form 4: Lucira Health, Inc. (LHDX), Allen Anthony Joseph, transaction 03/03/2023
- Form 4: Lucira Health, Inc. (LHDX), Allen Anthony Joseph, transaction 09/30/2021
- Form 4: Lucira Health, Inc. (LHDX), Collins Kevin Walter, transaction 03/03/2023
- Form 4: Lucira Health, Inc. (LHDX), Collins Kevin Walter, transaction 05/27/2022
- Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 02/04/2021
- Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 02/09/2021
- Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 03/03/2023
- Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 03/15/2022
- Form 4: Lucira Health, Inc. (LHDX), Engelson Erik T., transaction 06/16/2022
- Form 4: Lucira Health, Inc. (LHDX), Gardiner Sandra A., transaction 06/01/2022
- Form 4: Lucira Health, Inc. (LHDX), George Dan, transaction 02/04/2021
- Form 4: Lucira Health, Inc. (LHDX), George Dan, transaction 02/09/2021
- Form 4: Lucira Health, Inc. (LHDX), George Dan, transaction 06/18/2021
- Form 4: Lucira Health, Inc. (LHDX), George Dan, transaction 06/18/2022
- Form 4: Lucira Health, Inc. (LHDX), Hartmann Hansgregory C., transaction 02/04/2021
- Form 4: Lucira Health, Inc. (LHDX), Hartmann Hansgregory C., transaction 03/10/2021
- Form 4: Lucira Health, Inc. (LHDX), Hartmann Hansgregory C., transaction 06/18/2021
- Form 4: Lucira Health, Inc. (LHDX), Kashmolah Ghazi, transaction 09/30/2021
- Form 4: Lucira Health, Inc. (LHDX), Lamond David, transaction 02/09/2021
- Form 4: Lucira Health, Inc. (LHDX), Lamond David, transaction 06/01/2022
- Form 4: Lucira Health, Inc. (LHDX), McCauley Alison, transaction 06/01/2022
- Form 4: Lucira Health, Inc. (LHDX), McCauley Alison, transaction 12/17/2021
- Form 4: Lucira Health, Inc. (LHDX), Mitra Debkishore, transaction 02/04/2021
- Form 4: Lucira Health, Inc. (LHDX), Mitra Debkishore, transaction 03/10/2021
- Form 4: Lucira Health, Inc. (LHDX), Narido Richard Clavano, transaction 03/03/2023
- Form 4: Lucira Health, Inc. (LHDX), Prashar Tamanna, transaction 02/04/2021
- Form 4: Lucira Health, Inc. (LHDX), Prashar Tamanna, transaction 03/01/2022
- Form 4: Lucira Health, Inc. (LHDX), Prashar Tamanna, transaction 03/10/2021
- Form 4: Lucira Health, Inc. (LHDX), Prashar Tamanna, transaction 06/09/2021
- Form 4: Lucira Health, Inc. (LHDX), Rogers Erica J., transaction 06/01/2022
- Form 4: Lucira Health, Inc. (LHDX), Susan Lior, transaction 02/09/2021
- Form 4: Lucira Health, Inc. (LHDX), Susan Lior, transaction 06/01/2022
- Form 4: Lucira Health, Inc. (LHDX), Tablak Steve, transaction 06/01/2022
- Form 4: Lucira Health, Inc. (LHDX), Yen Tuff, transaction 02/09/2021
- Form 4: Lucira Health, Inc. (LHDX), Yen Tuff, transaction 06/01/2022
- Form 4: Novavax Inc (NVAX), Glenn Gregory M, transaction 09/15/2021
- Form 4: Novavax Inc (NVAX), Herrmann John A III, transaction 09/15/2021
- Form 4: Novavax Inc (NVAX), King Rachel K., transaction 06/10/2022
- Form 4: Novavax Inc (NVAX), King Rachel K., transaction 06/17/2022
- Form 4: Ocugen, Inc. (OCGN), Castillo Kirsten, transaction 06/07/2022
- Form 4: Ocugen, Inc. (OCGN), Fernandes Prabhavathi, transaction 06/07/2022
- Form 4: Ocugen, Inc. (OCGN), Kompella Uday, transaction 06/07/2022
- Form 4: Ocugen, Inc. (OCGN), Kumar Ramesh, transaction 06/07/2022
- Form 4: Ocugen, Inc. (OCGN), Kumar Ramesh, transaction 12/16/2021
- Form 4: Ocugen, Inc. (OCGN), Musunuri Shankar, transaction 01/03/2022
- Form 4: Ocugen, Inc. (OCGN), Musunuri Shankar, transaction 12/16/2021
- Form 4: Ocugen, Inc. (OCGN), Potti Manish, transaction 12/16/2021
- Form 4: Ocugen, Inc. (OCGN), Subramanian Sanjay, transaction 01/03/2022
- Form 4: Ocugen, Inc. (OCGN), Subramanian Sanjay, transaction 12/16/2021
- Form 4: Ocugen, Inc. (OCGN), Whittington Marna C, transaction 06/07/2022
- Form 4: Ocugen, Inc. (OCGN), Zhang Junge, transaction 06/07/2022
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Asghar Najjam, transaction 03/16/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Asghar Najjam, transaction 11/12/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Czerepak Elizabeth, transaction 05/18/2022
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Czerepak Elizabeth, transaction 11/18/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Followwill Dorman, transaction 06/15/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Followwill Dorman, transaction 08/30/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Followwill Dorman, transaction 12/16/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 04/12/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 06/15/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 08/07/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 08/30/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 09/13/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 09/27/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 06/15/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 08/30/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 09/29/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 10/16/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Lee Edgar, transaction 06/15/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Lemus David, transaction 06/15/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Lemus David, transaction 08/30/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Reilly Tammy, transaction 05/18/2022
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Shah Jaisim, transaction 06/15/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Shah Jaisim, transaction 08/30/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Shao Jiong, transaction 06/15/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Smith Robin L, transaction 03/05/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Smith Robin L, transaction 06/15/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Smith Robin L, transaction 08/30/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Smith Robin L, transaction 09/03/2021
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Wu Yue Alexander, transaction 06/15/2020
- Form 4: Sorrento Therapeutics, Inc. (SRNE), Wu Yue Alexander, transaction 08/30/2021
- Form 4: Translate Bio, Inc. (TBIO), Barbier Ann, transaction 03/03/2020
- Form 4: Translate Bio, Inc. (TBIO), Barbier Ann, transaction 03/09/2021
- Form 4: Translate Bio, Inc. (TBIO), Beckman Daniella, transaction 06/16/2020
- Form 4: Translate Bio, Inc. (TBIO), Beckman Daniella, transaction 06/16/2021
- Form 4: Translate Bio, Inc. (TBIO), Beckman Daniella, transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Burgess Paul D., transaction 03/03/2020
- Form 4: Translate Bio, Inc. (TBIO), Burgess Paul D., transaction 03/09/2021
- Form 4: Translate Bio, Inc. (TBIO), Burgess Paul D., transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Demetri George, transaction 06/16/2020
- Form 4: Translate Bio, Inc. (TBIO), Demetri George, transaction 06/16/2021
- Form 4: Translate Bio, Inc. (TBIO), Demetri George, transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 06/16/2020
- Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 06/16/2021
- Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 08/25/2020
- Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Formela Jean Francois, transaction 12/21/2020
- Form 4: Translate Bio, Inc. (TBIO), Hughes Owen, transaction 06/16/2020
- Form 4: Translate Bio, Inc. (TBIO), Hughes Owen, transaction 06/16/2021
- Form 4: Translate Bio, Inc. (TBIO), Hughes Owen, transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Lynch Daniel, transaction 06/16/2020
- Form 4: Translate Bio, Inc. (TBIO), Meyer Robert J., transaction 06/16/2020
- Form 4: Translate Bio, Inc. (TBIO), Meyer Robert J., transaction 06/16/2021
- Form 4: Translate Bio, Inc. (TBIO), Meyer Robert J., transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Plenge Robert M, transaction 06/16/2020
- Form 4: Translate Bio, Inc. (TBIO), Plenge Robert M, transaction 06/16/2021
- Form 4: Translate Bio, Inc. (TBIO), Plenge Robert M, transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 01/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 03/03/2020
- Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 03/09/2021
- Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 04/07/2021
- Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 11/16/2020
- Form 4: Translate Bio, Inc. (TBIO), Sanofi, transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Schroer John R., transaction 03/03/2020
- Form 4: Translate Bio, Inc. (TBIO), Smith Brendan, transaction 04/19/2021
- Form 4: Translate Bio, Inc. (TBIO), Smith Brendan, transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Sutherland Everett Rand, transaction 03/22/2021
- Form 4: Translate Bio, Inc. (TBIO), Sutherland Everett Rand, transaction 09/14/2021
- Form 4: Translate Bio, Inc. (TBIO), Wooster Richard, transaction 03/03/2020
- Form 4: Translate Bio, Inc. (TBIO), Wooster Richard, transaction 03/09/2021
- Form 4: Vaxart, Inc. (VXRT), Cummings James F., transaction 03/28/2022
- Form 4: Vaxart, Inc. (VXRT), Finney Michael J., transaction 06/08/2020
- Form 4: Vaxart, Inc. (VXRT), Finney Michael J., transaction 06/16/2021
- Form 4: Vaxart, Inc. (VXRT), Finney Michael J., transaction 08/04/2022
- Form 4: Vaxart, Inc. (VXRT), Wheadon David E., transaction 06/16/2021
- Form 4: Vaxart, Inc. (VXRT), Wheadon David E., transaction 08/04/2022
- Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 01/10/2022
- Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 06/08/2020
- Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 06/11/2021
- Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 06/16/2021
- Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 08/04/2022
- Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 08/19/2022
- Form 4: Vaxart, Inc. (VXRT), Yedid Robert A., transaction 08/24/2022
- Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 06/02/2022
- Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 06/08/2022
- Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 08/12/2022
- Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 08/18/2022
- Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 08/24/2022
- Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 08/30/2022
- Form 4: Vir Biotechnology, Inc. (VIR), ARCH Venture Partners IX, LLC, transaction 09/02/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Hanly Ann M., transaction 02/22/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Hatfield Jeffrey S., transaction 05/23/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Horn Howard, transaction 02/17/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Horn Howard, transaction 02/22/2022
- Form 4: Vir Biotechnology, Inc. (VIR), More Robert J, transaction 05/23/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Nelsen Robert, transaction 12/20/2021
- Form 4: Vir Biotechnology, Inc. (VIR), Pang Phillip, transaction 02/22/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Perez Robert J, transaction 05/23/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Ramasastry Saira, transaction 05/23/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Rice Steven J., transaction 02/17/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Rice Steven J., transaction 02/22/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Sato Vicki L, transaction 12/20/2021
- Form 4: Vir Biotechnology, Inc. (VIR), Scangos George A, transaction 02/17/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Scangos George A, transaction 03/10/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Sigal Charles Elliott, transaction 05/23/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Virgin Herbert, transaction 02/17/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Virgin Herbert, transaction 02/22/2022
- Form 4: Vir Biotechnology, Inc. (VIR), Virgin Herbert, transaction 03/10/2022
- Form 6-K — CureVac N.V., data from Phase 2b/3 of First-Generation COVID-19 Vaccine, June 30, 2021
- Form 6-K — CureVac N.V.: acquisition of Frame Cancer Therapeutics (June 8, 2022)
- Form 6-K — CureVac N.V.: appointment of Dr. Malte Greune as Chief Operating Officer (June 30, 2021)
- Form 6-K — CureVac N.V.: Chief Development Officer Klaus Edvardsen will leave the Company (June 8, 2022)
- Form 6-K — CureVac N.V.: contract with the German federal government to supply mRNA vaccines (April 11, 2022)
- Form 6-K — CureVac N.V.: convened the annual general meeting of shareholders for June 22, 2022 (June 1, 2022)
- Form 6-K — CureVac N.V.: data from the Phase 1 clinical trial of CV8102 (November 10, 2021)
- Form 6-K — CureVac N.V.: departure of the Company's Chief Technology Officer (January 17, 2022)
- Form 6-K — CureVac N.V.: dievini, KfW and Dietmar Hopp amended the KfW dievini Shareholders' Agreement (2022)
- Form 6-K — CureVac N.V.: dosed the first participant, Phase 1 seasonal influenza vaccine candidate (2022)
- Form 6-K — CureVac N.V.: Dr. Ingmar Hoerr withdrew his candidacy for the Supervisory Board (June 23, 2021)
- Form 6-K — CureVac N.V.: financial results for the first quarter of 2022 (May 25, 2022)
- Form 6-K — CureVac N.V.: financial results for the fourth quarter and full-year of 2021 (April 28, 2022)
- Form 6-K — CureVac N.V.: financial results for the second quarter and first half of 2021 (August 16, 2021)
- Form 6-K — CureVac N.V.: financial results for the second quarter and first half of 2022 (August 18, 2022)
- Form 6-K — CureVac N.V.: financial results for the third quarter and nine months of 2021 (November 18, 2021)
- Form 6-K — CureVac N.V.: financial results for the third quarter and nine months of 2022 (November 17, 2022)
- Form 6-K — CureVac N.V.: first participant was dosed in a Phase 1 study of CV2CoV, with GSK (March 30, 2022)
- Form 6-K — CureVac N.V.: formation of CureVac RNA Printer GmbH, Markus Bergmann General Manager (2022)
- Form 6-K — CureVac N.V.: HERALD study data of CVnCoV in Preprints with The Lancet (August 31, 2021)
- Form 6-K — CureVac N.V.: Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021
- Form 6-K — CureVac N.V.: Interim Condensed Consolidated Financial Statements as of June 30, 2022
- Form 6-K — CureVac N.V.: Interim Condensed Consolidated Financial Statements as of March 31, 2022
- Form 6-K — CureVac N.V.: Interim Condensed Consolidated Financial Statements as of September 30, 2021
- Form 6-K — CureVac N.V.: Interim Condensed Consolidated Financial Statements as of September 30, 2022
- Form 6-K — CureVac N.V.: lawsuit in the German Regional Court, intellectual property rights (July 5, 2022)
- Form 6-K — CureVac N.V.: Phase 1 study of the COVID-19 mRNA vaccine candidate CV0501 (August 18, 2022)
- Form 6-K — CureVac N.V.: pre-clinical data for mRNA-encoded HNF4A in liver fibrosis (August 30, 2021)
- Form 6-K — CureVac N.V.: preclinical data of the second-generation vaccine candidate, CV2CoV (August 16, 2021)
- Form 6-K — CureVac N.V.: preclinical data, bivalent second-generation vaccine candidate (April 21, 2022)
- Form 6-K — CureVac N.V.: preliminary data from a Phase 1 expansion study of CV8102 (November 11, 2022)
- Form 6-K — CureVac N.V.: publication in Nature of preclinical data from CV2CoV (November 18, 2021)
- Form 6-K — CureVac N.V.: research and option agreement with myNEO N.V. (May 25, 2022)
- Form 6-K — CureVac N.V.: sales of common shares by members of its management team (December 14, 2022)
- Form 6-K — CureVac N.V.: tabulations of the votes cast at the Company's annual general meeting (June 27, 2022)
- Form 6-K — CureVac N.V.: tabulations of the votes cast at the Company's annual general meeting (June 29, 2021)
- Form 6-K — CureVac N.V.: termination of manufacturing contracts with Wacker Chemie AG (September 14, 2021)
- Form 6-K — CureVac N.V.: Update Regarding Timeline of Programs, J.P. Morgan Healthcare Conference (2022)
- Form 6-K — CureVac N.V.: voting results of the annual general meeting of shareholders (June 22, 2022)
- Form 6-K — CureVac N.V.: voting results of the annual general meeting of shareholders (June 24, 2021)
- Form 6-K — CureVac N.V.: withdraw CVnCoV from the approval process with the European Medicines Agency (2021)
- Form 6-K — Thomson Reuters Corporation (May 2021)
- FORM 8-K CURRENT REPORT — HIMS & HERS HEALTH, INC. (January 20, 2021)
- Form 8-K Current Report — United States Securities and Exchange Commission
- Form 8-K — Crossroads Systems, Inc. (Date of Report: August 14, 2017)
- Form 8-K — Infinite Group, Inc. (Date of Report: March 29, 2023)
- Form 8-K — Shake Shack Inc.: returning $10.0 million in proceeds from a loan, Paycheck Protection Program
- Form 8-K, Bankruptcy or Receivership — Cue Health Inc. (May 16, 2024)
- Form 8-K, Item 2.05 Costs Associated with Exit or Disposal Activities — Eventbrite, Inc. (April 8, 2020)
- Form 8-K, Item 5.02 Departure of Directors or Certain Officers — Enova International, Inc. (July 24, 2025)
- Form 8-K, Other Events — Customers Bancorp, Inc. (October 27, 2022)
- Form 8-K, Sorrento Therapeutics: ACEA Therapeutics, Inc. binding term sheet (October 14, 2020)
- Form 8-K, Sorrento Therapeutics: First Amendment to Exchange and Registration Rights Agreement, Semnur (2020)
- Form 8-K, Sorrento Therapeutics: Phase 2 clinical trial of Abivertinib in COVID-19 patients (October 14, 2020)
- Form 8-K, Sorrento Therapeutics: preclinical data on STI-1499 and STI-2020 neutralizing antibodies (2020)
- Form 8-K, Termination of a Material Definitive Agreement — Cue Health Inc. (May 16, 2024)
- Form 907, Agreement to Extend the Time to Bring Suit — Internal Revenue Service (January 2026)
- Form 941 and Schedule B (Form 941) for PEI STAFFING LLC — Document 30-4, No. 1:23-cr-00210-RDB
- Form 941 and Schedule B (Form 941) for PEI STAFFING LLC, 2019 — Document 30-3
- Form 941 for 2019 — PEI STAFFING LLC, Case 1:23-cr-00210-RDB, Document 30-6
- Form 941-X: Adjusted Employer’s Quarterly Federal Tax Return or Claim for Refund (Rev. April 2023)
- Form 941-X: Adjusted Employer’s Quarterly Federal Tax Return or Claim for Refund (Rev. April 2026)
- Form 943-X: Adjusted Employer’s Annual Federal Tax Return for Agricultural Employees or Claim for Refund
- Form 944-X: Adjusted Employer’s ANNUAL Federal Tax Return or Claim for Refund (Rev. February 2023)
- Form 9: Application for Access to Information Under Protective Order by Outside or Inside Counsel — Case 1:24-cv-00365-PSH (Dkt. 16)
- Form AACPO-I, Vanguard Brokerage Account — Case 5:24-cr-00292-PCP, Document 44-38
- Form CT-1 X: Adjusted Employer's Annual Railroad Retirement Tax Return or Claim for Refund (March 2023)
- Form D, Gaingels Wonderschool 2021 LLC
- Form D, SmartBiz Bancshares, Inc. (filed 2025-05-02)
- Form D, Sojern Inc, accession 0001437308-23-000004
- Form D/A, Sojern Inc, accession 0001437308-23-000005
- Form OCR solutions: Automate form data extraction
- Form of Auction Participation Agreement
- Form of Declaration of Disinterestedness — In re Vyaire Medical
- Form of Order Extending the Debtors' Exclusive Periods — In re Kabbage, Inc. d/b/a KServicing
- Form of Securities Purchase Agreement as of 5/23/2024
- Form RD 1980-44 — Guaranteed Loan Borrower Default Status (USDA Rural Development)
- Form S-1 Registration Statement, Cue Health Inc., As Filed September 1, 2021
- Form S-1/A (Amendment No. 1) — Cue Health Inc. (Filed September 15, 2021)
- Former Amtrak Employee and Her Husband Plead Guilty to Charges for Fraudulently Obtaining Nearly $1 Million in COVID Jobless Relief
- Former Amtrak Employee Pleads Guilty to Cares Act Fraud and Theft
- Former Amtrak Employee Sentenced to Over 2 Years in Prison for Crimes, Including Near-$1 Million COVID Jobless Benefits Fraud
- Former Arizona Man Sentenced to 5 Years for Stealing Mainersʼ Identities
- Former Arizona Man Sentenced to 5 Years for Stealing Mainers’ Identities in Pandemic Unemployment Fraud
- Former Assistant Atlanta City Attorney and Police Officer Charged in $7 Million PPP Fraud Scheme
- Former Assistant Atlanta City Attorney and Police Officer Charged in $7 Million PPP Fraud Scheme — Shelitha Robertson, Atlanta
- Former Atlanta business-owner sentenced to prison for obtaining millions of dollars in COVID-19 relief fraud
- Former Atlanta Housing Authority Official Sentenced for Fraud
- Former Baltimore City Council Candidate Convicted of Bank Fraud
- Former Baltimore City Council Candidate Sentenced for Bank Fraud
- Former Bangor Business Owner Pleads Guilty to Paycheck Protection Plan (PPP) Loan Fraud
- Former Bangor Business Owner Sentenced to 20 Months for Paycheck Protection Plan (PPP) Loan Fraud
- Former Bank Vice President Sentenced to Four Years in Federal Prison For Fraudulent PPP and EIDL Fraud Scheme
- Former Banker Sentenced for Defrauding Bank Through PPP Loans
- Former Banker Sentenced to Prison for Role in Movie Financing Fraud Scheme, Falsely Applying for COVID-19 Loans
- Former Blackberry Volunteer Fire Chief Pleads Guilty to COVID-19 Fraud
- Former Blackberry Volunteer Fire Chief Sentenced for COVID-19 Fraud
- Former Blue Springs Woman Pleads Guilty to $220,000 Covid Fraud